Lifeboat Foundation

https://www.youtube.com/watch?v=JEdVe0IlHyc

I recently interviewed post-humanist Dr Francesca Ferrando on the relationship between the global transhumanist and post-humanist movements – might be of interest!

Blown away by the support since I launched my YouTube channel focused on futurist/transhumanist topics a couple of months back & have decided to invest in better equipment to boost the quality. In the meantime very grateful for any subscribers 😊.

Continue reading “‘I consider myself a post-humanist’ — Francesca Ferrando interview” »

A United Arab Emirates research institute has developed a coronavirus treatment using stem cells “which could be a game-changer in the global fight” against the outbreak, a government official announced on Friday.

Read the latest coronavirus updates in our dedicated section.

The Abu Dhabi Stem Cell Center has developed a treatment method that regenerates lung cells and prevents the immune system from overreacting, Hend Al Otaiba, Director of Strategic Communications with the Ministry of Foreign Affairs, said in a Twitter thread.

The director of our institute, Sir Paul Nurse, borrowed another wartime analogy when he imagined academic labs as a flotilla of ‘little ships’, as at Dunkirk, that could be set up quickly to help rescue a rather desperate situation. The protocols we’ve developed have been downloaded more than 5,000 times, and we’ve helped other testing laboratories (including the big ones that are now coming online) with re-agents and scientific advice. We’ve been able to get recovering doctors and nurses back to work quicker, and crucially we’ve been able to identify healthcare workers who may have been spreading the virus unwittingly to the most vulnerable.

The team at the Crick is extremely multi-national. Wartime analogies are not helpful when they promote national exceptionalism, still less when they imply an individual battle between patient and virus. They are helpful when it comes to getting people to think clearly and act swiftly. The frustration when we’ve run up against what might be politely described as ‘NHS bureaucracy’ has been intense. When we’ve dealt with local NHS partners who are determined and dynamic, we’ve been able to save lives. In this sense there really is a war on, and for once I’m happy to see politicians treat it in this way.

We will win this war through immunity. Understanding immunity to respiratory viruses is really difficult — more like decoding Enigma than developing radar. We will need new technology as well as optimising existing tests. So far, the best tests can give a reasonable estimate of whether someone has been exposed to the virus. They cannot yet tell you if you are immune to it. The trouble with coronaviruses is that they have evolved to evade immunity. They possess all sorts of unknown weaponry that dampens down our immune responses.

General anesthesia (GA) can produce analgesia (loss of pain) independent of inducing loss of consciousness, but the underlying mechanisms remain unclear. We hypothesized that GA suppresses pain in part by activating supraspinal analgesic circuits. We discovered a distinct population of GABAergic neurons activated by GA in the mouse central amygdala (CeA_GA neurons). In vivo calcium imaging revealed that different GA drugs activate a shared ensemble of CeA_GA neurons also possess basal activity that mostly reflects animals’ internal state rather than external stimuli. Optogenetic activation of CeA_GA potently suppressed both pain-elicited reflexive and self-recuperating behaviors across sensory modalities and abolished neuropathic pain-induced mechanical (hyper-)sensitivity. Conversely, inhibition of CeA_GA activity exacerbated pain, produced strong aversion and canceled the analgesic effect of low-dose ketamine. CeA_GA neurons have widespread inhibitory projections to many affective pain-processing centers. Our study points to CeA_GA as a potential powerful therapeutic target for alleviating chronic pain.

A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first identified in December 2019 as the cause of a respiratory illness designated coronavirus disease 2019, or Covid-19.¹ Several therapeutic agents have been evaluated for the treatment of Covid-19, but none have yet been shown to be efficacious.^2,3 Remdesivir (GS-5734), an inhibitor of the viral RNA-dependent, RNA polymerase with inhibitory activity against SARS-CoV and the Middle East respiratory syndrome (MERS-CoV),^4–7 was identified early as a promising therapeutic candidate for Covid-19 because of its ability to inhibit SARS-CoV-2 in vitro.⁸ In addition, in nonhuman primate studies, remdesivir initiated 12 hours after inoculation with MERS-CoV^9,10 reduced lung virus levels and lung damage.

To evaluate the clinical efficacy and safety of putative investigational therapeutic agents among hospitalized adults with laboratory-confirmed Covid-19, we designed an adaptive platform to rapidly conduct a series of phase 3, randomized, double-blind, placebo-controlled trials. Here, we describe the preliminary results of the first stage of the Adaptive Covid-19 Treatment Trial (ACTT-1), in which we evaluated treatment with remdesivir as compared with placebo.

Data from millions of smartphones tells us which parts of the country have reopened.

U.S. Military Soldiers conduct training on the Common Remotely Operated Weapon Station (CROWS).

CROWS is a stabilized mount that contains a sensor suite and fire control software, allowing on-the-move target acquisition and first-burst target engagement. CROWS also features programmable target reference points for multiple locations, programmable sector surveillance scanning, automatic target ballistic lead, automatic target tracking, and programmable no-fire zones.

Continue reading “CROWS Remote Machine Gun System In Action” »

It was fun speaking on STC webinar today.

Moderna’s stock price skyrocketed as much as 30% on Monday after the biotech company announced promising early results for its coronavirus vaccine. As ordinary investors piled in, two insiders were quietly heading for the exits.

Moderna’s chief financial officer and chief medical officer executed options and sold nearly $30 million of shares combined on Monday and Tuesday, SEC filings reviewed by CNN Business show.

The sales occurred after Moderna (MRNA) excited Wall Street before markets opened Monday by announcing encouraging vaccine trial results. Moderna’s market value swelled to $29 billion — even though the company has no marketed products.